8-K: Relay Therapeutics and Genentech Collaboration Agreement Terminated

Relay Therapeutics has received notice from Genentech to terminate their collaboration agreement for the development of RLY-1971, effective in 180 days.

Summary

• Relay Therapeutics received notice from Genentech to terminate their collaboration and license agreement, effective 180 days from July 11, 2024.
• The agreement was for the development and commercialization of RLY-1971, now known as migoprotafib or GDC-1971.
• Relay Therapeutics received a total of $121.8 million from Genentech, including a $75 million upfront payment and $45 million in milestone payments.
• Following the termination, Relay Therapeutics will not receive any further milestone or other payments.
• Both parties will cease development and commercialization obligations, and licenses granted to Genentech will be terminated.

Sentiment

Score: 4

Explanation: The termination of a key collaboration agreement is a negative development, although the company has already received a significant sum. The need to independently fund future development introduces uncertainty.

Positives

• Relay Therapeutics has already received $121.8 million from Genentech under the agreement.
• Relay Therapeutics will regain full control of the development and commercialization of RLY-1971.

Negatives

• Relay Therapeutics will not receive any further milestone payments from Genentech.
• Relay Therapeutics will need to fund the future development and commercialization of RLY-1971 independently.

Risks

• Relay Therapeutics will need to secure funding for the continued development of RLY-1971.
• The termination of the agreement may negatively impact investor confidence.
• The company will need to establish its own commercialization strategy for RLY-1971.

Future Outlook

Relay Therapeutics will need to independently pursue the development and commercialization of RLY-1971 after the termination date.

Industry Context

The termination of this collaboration agreement is not uncommon in the pharmaceutical industry, where companies often adjust their portfolios based on strategic priorities and clinical trial results. This may indicate a shift in Genentech's focus or a change in their assessment of the potential of RLY-1971.

Comparison to Industry Standards

• Collaboration terminations are a common occurrence in the biotech industry, often due to shifting priorities or clinical trial results.
• Similar agreements between companies like Pfizer and BioNTech, or AstraZeneca and Oxford University, have also seen adjustments or terminations based on various factors.
• The $121.8 million received by Relay Therapeutics is within the range of upfront and milestone payments seen in similar early-stage drug development collaborations.
• The 180-day termination period is a standard timeframe for such agreements, allowing for a smooth transition of responsibilities.

Stakeholder Impact

• Shareholders may react negatively to the termination of the agreement.
• Employees involved in the RLY-1971 program may experience uncertainty.
• The company's future financial performance may be impacted by the loss of potential milestone payments.

Next Steps

• Relay Therapeutics will need to reassess its strategy for RLY-1971.
• Relay Therapeutics will need to secure funding for the continued development of RLY-1971.
• Relay Therapeutics will need to establish its own commercialization strategy for RLY-1971.

Key Dates

Keywords

Relay Therapeutics, Genentech, Collaboration Agreement, RLY-1971, Migoprotafib, GDC-1971, Termination, License Agreement, Pharmaceuticals, Drug Development